Sugi Predict

Sugi Predict / Targets / CYP17A1

CYP17A1

Steroid 17-alpha-hydroxylase/17,20 lyase · P05093 · CYP17A1 on Sugi Atlas →

112,207 patent compounds predicted against CYP17A1, 57,535 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL358823 SCHEMBL358823 1.00 20/20
SCHEMBL367349 SCHEMBL367349 1.00 20/20
SCHEMBL367579 SCHEMBL367579 1.00 20/20
SCHEMBL367860 SCHEMBL367860 1.00 20/20
SCHEMBL367931 SCHEMBL367931 1.00 20/20
SCHEMBL368118 SCHEMBL368118 1.00 20/20
SCHEMBL368521 SCHEMBL368521 1.00 20/20
SCHEMBL368532 SCHEMBL368532 1.00 20/20
SCHEMBL368661 SCHEMBL368661 1.00 20/20
SCHEMBL368858 SCHEMBL368858 1.00 20/20
SCHEMBL367206 SCHEMBL367206 0.84 20/20
SCHEMBL368329 SCHEMBL368329 0.82 20/20
SCHEMBL368338 SCHEMBL368338 0.80 20/20
SCHEMBL368213 SCHEMBL368213 0.79 20/20
SCHEMBL368586 SCHEMBL368586 0.78 20/20
SCHEMBL367748 SCHEMBL367748 0.77 20/20
SCHEMBL368781 SCHEMBL368781 0.76 20/20
SCHEMBL368082 SCHEMBL368082 0.76 20/20
SCHEMBL368470 SCHEMBL368470 0.75 20/20
SCHEMBL368256 SCHEMBL368256 0.74 20/20

Clinical trials — most relevant to CYP17A1 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Congenital Adrenal Hyperplasia Once Daily Hydrocortisone Treatment PHASE4RECRUITING
Abiraterone Acetate in Castration-Resistant Prostate Cancer Previously Treated With Docetaxel-Based Chemotherapy PHASE3COMPLETED
Orteronel Maintenance Therapy in Patients With mCRPC Previously Treated With Novel Hormonal Agents PHASE3WITHDRAWN
Theca Cell Function in Adolescents With Polycystic Ovary Syndrome (PCOS) PHASE3COMPLETED
Androgen Reduction in Congenital Adrenal Hyperplasia PHASE2WITHDRAWN
Activity of Abiraterone Acetate in the Management of Cushing's Syndrome in Patients With Adrenocortical Carcinoma PHASE2UNKNOWN
A Novel Aromatase Inhibitor, Leflutrozole, for Treatment of Non-Obstructive Azoospermia PHASE1/PHASE2NOT_YET_RECRUITING
AMG 386 and Abiraterone for Advanced Prostate Cancer PHASE2COMPLETED
Study of Dose Escalation of Abiraterone Actetate in Prostate Cancer PHASE2COMPLETED
Abiraterone With Discontinuation of Gonadotropin-Releasing Hormone Analogues in Metastatic Prostate Cancer PHASE2COMPLETED
CYP17 Lyase and Androgen Receptor Inhibitor Treatment With Seviteronel Trial (INO-VT-464-006; NCT02580448) PHASE1/PHASE2COMPLETED
A Phase 2 Study to Evaluate the Effects of ASP5541 in Participants With Prostate Cancer PHASE2RECRUITING
The Impact of Medication Timing Adjustment on the Effect of Novel Hormonal Therapy PHASE2NOT_YET_RECRUITING
A Study Examining Doses of Abiraterone Acetate in Adult Women With 21-Hydroxylase Deficiency PHASE1COMPLETED
Phase 1 Study of ATRS-2002 in Healthy Male Adults PHASE1WITHDRAWN
A Study to Evaluate the Safety and Drug Levels of ASP5541 in Chinese Participants With Prostate Cancer PHASE1RECRUITING
A Study of Comparative Formulations of Niraparib and Abiraterone Acetate (AA) in Men With Prostate Cancer PHASE1ACTIVE_NOT_RECRUITING
Mutation Analysis of 17α-Hydroxylase nanUNKNOWN
Polycystic Ovary Syndrome in Type 1 Diabetes nanNOT_YET_RECRUITING
Final Height in Patients With CAH nanUNKNOWN
Mutation Analysis of 17βhydroxysteroid Dehydrogenase 3 Deficiency nanUNKNOWN
Determining the Long-Term Effects of Prenatal Dexamethasone Treatment in Children With 21-Hydroxylase Deficiency and Their Mothers nanUNKNOWN
Evaluating a Personalised Online Program With Human Support for Women With Depression and Its Impact on Mental Health and Biological Changes nanNOT_YET_RECRUITING
Ovarian Morphology and Theca Cell Androgen Production in Women With Polycystic Ovary Syndrome (PCOS) nanCOMPLETED
Furocyst - Poly Cystic Ovary Syndrome Study nanCOMPLETED
A Prospective Observational Study of Biomarkers for a Personalised IVF Treatment nanUNKNOWN
Early Mental Response - The EMRE Study nanRECRUITING
Examining Genetic Differences Among People With 21-Hydroxylase Deficiency nanCOMPLETED
Biomarkers in Bone Marrow and Blood Samples From Patients With Prostate Cancer Treated With Ketoconazole nanWITHDRAWN
Linear Growth of Children With Congenital Adrenal Hyperplasia nanUNKNOWN

Related proteins — ESM-2 sequence neighbours (a CYP17A1 binder may also engage these)

ProteinNameSimilarity
Q8HYN1 — 1.000 Q8HYN1 →
Q8HYM9 — 1.000 Q8HYM9 →
Q8HYN0 — 1.000 Q8HYN0 →
Q95328 — 1.000 Q95328 →
Q9GLD2 — 1.000 Q9GLD2 →
Q2XVA1 — 1.000 Q2XVA1 →
Q9N0U7 — 1.000 Q9N0U7 →
P05185 — 1.000 P05185 →
Q29497 — 1.000 Q29497 →
Q9GMC7 — 1.000 Q9GMC7 →
Q9GMC8 — 1.000 Q9GMC8 →
P27786 — 1.000 P27786 →
P70687 — 0.998 P70687 →
Q64410 — 0.997 Q64410 →
P11715 — 0.997 P11715 →
O73853 — 0.997 O73853 →
Q91Z85 — 0.997 Q91Z85 →
P19100 — 0.996 P19100 →
O57525 — 0.995 O57525 →
Q92113 — 0.995 Q92113 →
Q50LH4 — 0.993 Q50LH4 →
P30437 — 0.992 P30437 →
Q50LH3 — 0.992 Q50LH3 →
A0A0G2RKY1 — 0.992 A0A0G2RKY1 →
C0SPF7 — 0.991 C0SPF7 →
B1NF20 — 0.991 B1NF20 →
Q55AJ4 — 0.991 Q55AJ4 →
B5UAQ8 — 0.990 B5UAQ8 →
P82713 — 0.990 P82713 →
Q9VGB5 — 0.990 Q9VGB5 →